Of the 103 patients who completed the Phase III trial, more than half witnessed remission from a drug-induced condition that ...

US neuroscience-focused biopharma Neurocrine Biosciences (Nasdaq: NBIX) today presented new data from the long-term, ...

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the long-term, open-label KINECT® 4 study demonstrating remission of tardive dyskinesia among the majority of patients treated ...

CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for double-digit year ...

Now Neurocrine Bioscience, with Ingrezza and elagolix not far behind it, could become a significant mid-size company within just a few years. Andrew McConaghie 11 April, 2017 ...

Biosciences presented data from the KINECT-HD study showcasing significant improvements in chorea across body regions with ...

Ingrezza remains the main revenue driver, with a 23% increase in quarterly sales to $615 million. Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key ...

Neurocrine Biosciences ... The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules ...

(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) Monday said it presented positive data from Phase 3 KINECT-HD study evaluating Ingrezza capsule in adults with Huntington's disease at the ...